MedTrace Logo

SCT in Ph Positive Acute Lymphoblastic Leukemia

NCT03821727 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 441

Last updated 2019-01-30

No results posted yet for this study

Summary

This study includes a registry-based, nationwide analysis to describe the clinical outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) after a Tyrosine Kinase Inhibitors (TKI)-based treatment.

Conditions

  • Philadelphia Positive Acute Lymphoblastic Leukemia
  • SCT

Interventions

PROCEDURE

Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation in Acute Leukemia Ph positive

Sponsors & Collaborators

  • Gruppo Italiano Trapianto di Midollo Osseo

    collaborator OTHER

  • CANDONI ANNA

    lead OTHER

Principal Investigators

  • Renato Fanin, Professor · University of Udine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-26
Primary Completion
2017-12-31
Completion
2018-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03821727 on ClinicalTrials.gov